595 related articles for article (PubMed ID: 23799935)
1. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
2. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
3. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
[TBL] [Abstract][Full Text] [Related]
5. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
[TBL] [Abstract][Full Text] [Related]
6. Role of immunmodulators in allergen-specific immunotherapy.
Kopp MV
Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.
Kopp MV; Stenglein S; Kamin W; Friedrichs F; von Berg A; Zielen S; Hamelmann E; Wahn U; Kuehr J
Pediatr Allergy Immunol; 2007 Sep; 18(6):523-7. PubMed ID: 17680911
[TBL] [Abstract][Full Text] [Related]
8. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
9. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
Okubo K; Ogino S; Nagakura T; Ishikawa T
Allergol Int; 2006 Dec; 55(4):379-86. PubMed ID: 17130680
[TBL] [Abstract][Full Text] [Related]
11. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
12. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
13. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
14. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms.
Crimi N; Li Gotti F; Mangano G; Paolino G; Mastruzzo C; Vancheri C; Lisitano N; Polosa R
Ann Ital Med Int; 2004; 19(2):98-108. PubMed ID: 15317270
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
17. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
[TBL] [Abstract][Full Text] [Related]
18. Phoenix sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India.
Chakraborty P; Roy I; Chatterjee S; Chanda S; Gupta-Bharracharya S
J Investig Allergol Clin Immunol; 2006; 16(6):377-84. PubMed ID: 17153886
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
20. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.
Pfaar O; Biedermann T; Klimek L; Sager A; Robinson DS
Allergy; 2013 Oct; 68(10):1306-13. PubMed ID: 23991896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
